PathAI and Labcorp have expanded their strategic collaboration, which will enable the deployment of the former’s algorithms in prospective clinical trials of cancer and other diseases.

Developed using Good Clinical Laboratory Practice (GCLP) guidelines and process controls, the PathAI algorithms will be deployed in the broad portfolio of programmes managed by Labcorp Drug Development.

The latest move builds on Labcorp’s previous investment in PathAI and aims to accelerate the use of artificial intelligence (AI)-powered pathology.

PathAI algorithms are locked and validated as fit for purpose and can also be further extended for development and commercialisation of companion diagnostic (CDx) device.

With many potential additional uses, they can also be integrated in retrospective or prospective clinical trials to quantify tissue-based biomarkers and support patient stratification and selection.

PathAI CEO Andy Beck said: “We are very impressed with the vision that Labcorp has for the future of AI-powered pathology in drug development and diagnostics, and we look forward to joining forces to enable our bio-pharma partners to obtain the most accurate, standardized, and data-rich set of pathology readouts from clinical trials to help advance drug development.

“After exploring successful initial projects with Labcorp, we are excited to leverage the scale of its network to grow the reach of digital and computational pathology with the goal of ultimately improving patient outcomes.”

As part of the collaboration, the two companies are also planning to explore bridging the use of AI-powered algorithms from translational research into a clinical laboratory setting.

Labcorp Drug Development CEO Paul Kirchgraber said: “This collaboration will provide our bio-pharma partners a differentiated understanding of relevant patient characteristics through applying leading AI-driven algorithms to support clinical trials from novel biomarker development through patient stratification and companion diagnostic development.”